France, May 28 -- The government has signed off on partially reimbursing patients who are prescribed Novo Nordisk's Wegovy and Eli Lilly's Mounjaro injectable GLP-1 medications, which have gained widespread attention as anti-obesity treatments.

The announcement was made official on Thursday, and reimbursement is expected to be effective by mid-June, Health Minister Stephanie Rist said on Thursday in an interview with TF1 television.

Wegovy and Mounjaro have been available in France for weight loss by prescription since 2024, but they had not been approved for reimbursement by the national health insurance system until now. That left patients paying the full cost of €300 per month.

The weight-loss drugs will now be reimbursed at t...